Status:
COMPLETED
Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa
Lead Sponsor:
AstraZeneca
Conditions:
Lung Cancer
Eligibility:
All Genders
Up to 130 years
Brief Summary
The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments,...
Detailed Description
Descriptive pharmacoepidemiological study of patients treated with Iressa
Eligibility Criteria
Inclusion
- Patients treated with Iressa
Exclusion
- Patient included in a therapeutic trial comprising protocol use of Iressa
- Patient included in a therapeutic trial (Huriet-Serusclat Act)
- Patient refusing to participate in the study
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
361 Patients enrolled
Trial Details
Trial ID
NCT01448187
Start Date
January 1 2012
End Date
March 1 2015
Last Update
July 4 2016
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aulnay-sous-Bois, France
2
Research Site
Bayonne, France
3
Research Site
Bordeaux, France
4
Research Site
Bron, France